deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03270514

Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride

Postoperative Analgesia After Cardiac Surgery - A Double-Blind, Prospective and Randomized Comparison of Wound Infiltration With Liposomal Bupivacaine and Bupivacaine Hydrochloride

Sponsor: Kathirvel Subramaniam

Conditions Coronary Artery Disease Coronary Artery Stenoses Valve Regurgitation, Mitral Valve Regurgitation, Tricuspid
Interventions Bupivacaine Hydrochloride Exparel Injectable Product
Updated 16 times since 2017 Last updated: Aug 10, 2021 Started: Nov 15, 2018 Primary completion: Dec 13, 2019 Completion: Feb 25, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Coronary Artery Disease and Coronary Artery Stenoses, this trial is completed. The trial is conducted by Kathirvel Subramaniam and has accumulated 16 data snapshots since 2018. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

~Oct 2017 – ~Apr 2018 · 6 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Sep 2019 · 8 months · monthly snapshot~Sep 2019 – ~May 2020 · 8 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Oct 2021 · 7 months · monthly snapshot~Oct 2021 – ~Dec 2022 · 14 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE3

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

  5. Oct 2021 — Dec 2022 [monthly]

    Completed PHASE3

▶ Show 11 earlier versions

  1. Mar 2021 — Oct 2021 [monthly]

    Completed PHASE3

  2. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE3

  3. May 2020 — Jan 2021 [monthly]

    Completed PHASE3

    Status: Recruiting → Completed

  4. Sep 2019 — May 2020 [monthly]

    Recruiting PHASE3

  5. Jan 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  6. Nov 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE3

  7. Sep 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE3

  8. Jul 2018 — Sep 2018 [monthly]

    Not Yet Recruiting PHASE3

  9. Jun 2018 — Jul 2018 [monthly]

    Not Yet Recruiting PHASE3

  10. Apr 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE3

  11. Oct 2017 — Apr 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kathirvel Subramaniam
  • Pacira Pharmaceuticals, Inc
Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations